[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses
Actas Dermo-Sifiliográficas · 2025-01 · 116 (1) · T55-T67
DOI: 10.1016/j.ad.2024.10.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2025-01. Verfasst von D Martín-Torregrosa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, IIS La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Antibodies, Monoclonal, Humanized, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous signs. Although anifrolumab has not been indicated for cutaneous lupus erythematosus (CLE), multiple cases and case series (20 publications with a total of 78 patients) have shown good and rapid responses with this drug, both in subacute CLE and discoid lupus erythematosus, as well as in lupus panniculitis and perniosis. Two case reports of dermatomyositis have also experienced clinical improvement with anifrolumab. Clinical trials of this drug are ongoing for subacute CLE and discoid lupus erythematosus, systemic sclerosis, and progressive vitiligo. Its most common adverse effects are respiratory infections and herpes zoster. Anifrolumab may be a well-tolerated alternative in the management of CLE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, IIS La Fe, Valencia, Spain.
- Servicio de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Girona, Spain; Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain. Electronic address: morgadodanie…
Zitieren
APA
Martín-Torregrosa, D., Mansilla-Polo, M., & Morgado-Carrasco, D. (2025). [Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses. Actas Dermo-Sifiliográficas, 116(1), T55-T67. https://doi.org/10.1016/j.ad.2024.10.008
Vancouver
Martín-Torregrosa D, Mansilla-Polo M, Morgado-Carrasco D. [Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses. Actas Dermo-Sifiliográficas. 2025;116(1):T55-T67. doi:10.1016/j.ad.2024.10.008
BibTeX
@article{MartnTorregrosa2025,
author = {Martín-Torregrosa, D and Mansilla-Polo, M and Morgado-Carrasco, D},
title = {[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses},
journal = {Actas Dermo-Sifiliográficas},
year = {2025},
volume = {116},
number = {1},
pages = {T55--T67},
doi = {10.1016/j.ad.2024.10.008}
}
EUVIMED